Last updated on March 2020

A Controlled Trial of Erenumab in Migraine Prevention


Brief description of study

Study is a phase 3 trial intended to assess the efficacy and safety of erenumab for prevention of migraine in Japanese subjects with episodic migraine (EM) and chronic migraine (CM).

Detailed Study Description

Migraine prevention is an area of a large unmet medical need, with existing therapies often having modest efficacy and poor tolerability. Calcitonin gene-related peptide (CGRP) receptor antagonism is a novel approach to migraine preventive therapy. Erenumab is a human monoclonal antibody against canonical CGRP receptor. The present study is a phase 3 trial intended to assess the efficacy and safety of erenumab for prevention of migraine in Japanese subjects with episodic migraine (EM) and chronic migraine (CM).

Clinical Study Identifier: NCT03812224

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.